Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.
You may also be interested in...
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
Using 1998 authority would reduce the burden on sponsors, physicians and patients, industry group says.
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
Using 1998 authority would reduce the burden on sponsors, physicians and patients, industry group says.
FDA Seeks To Write MedGuides Outside REMS Process
FDA is searching for a way out of imposing a REMS when only a medication guide is required